

HYDROXYZINE HCL- hydroxyzine hcl tablet
HYDROXYZINE HCL- hydroxyzine hcl tablet, film coated
HYDROXYZINE HYDROCHLORIDE- hydroxyzine hydrochloride tablet, film coated
DIRECT RX

HYDROXYZINE HCL 25mg

Hydroxyzine hydrochloride, USP has the chemical name of (\pm)-2-[2-[4-(p-Chloro- α -phenylbenzyl)-1-piperazinyl]ethoxy]ethanol dihydrochloride.

[structure]

Molecular Formula: C₂₁H₂₇ClN₂O₂ · 2HCl Molecular Weight: 447.83

Hydroxyzine hydrochloride, USP occurs as a white, odorless powder which is very soluble in water.

Each tablet for oral administration contains 10 mg, 25 mg, or 50 mg hydroxyzine hydrochloride, USP. Inactive ingredients include anhydrous lactose, colloidal silicon dioxide, croscopovidone, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate and titanium dioxide.

Hydroxyzine hydrochloride is unrelated chemically to the phenothiazines, reserpine, meprobamate or the benzodiazepines. Hydroxyzine is not a cortical depressant, but its action may be due to a suppression of activity in certain key regions of the subcortical area of the central nervous system.

Primary skeletal muscle relaxation has been demonstrated experimentally. Bronchodilator activity, and antihistaminic and analgesic effects have been demonstrated experimentally and confirmed clinically. An antiemetic effect, both by the apomorphine test and the veriloid test, has been demonstrated.

Pharmacological and clinical studies indicate that hydroxyzine in therapeutic dosage does not increase gastric secretion or acidity and in most cases has mild antisecretory activity.

Hydroxyzine is rapidly absorbed from the gastrointestinal tract and hydroxyzine's clinical effects are usually noted within 15 to 30 minutes after oral administration.

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.

Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus.

As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.

The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.

Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride.

Hydroxyzine is contraindicated in patients with a prolonged QT interval.

Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy.

Hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers.

THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES. Therefore, when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.

QT Prolongation/Torsade de Pointes (TdP): Cases of QT prolongation and Torsade de Pointes have been reported during post-marketing use of hydroxyzine. The majority of reports occurred in patients with other risk factors for QT prolongation/TdP (pre-existing heart disease, electrolyte imbalances or concomitant arrhythmogenic drug use). Therefore, hydroxyzine should be used with caution in patients with risk factors for QT prolongation, congenital long QT syndrome, a family history of long QT syndrome, other conditions that predispose to QT prolongation and ventricular arrhythmia, as well as recent myocardial infarction, uncompensated heart failure, and bradyarrhythmias.

Caution is recommended during the concomitant use of drugs known to prolong the QT interval. These include Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmics, certain antipsychotics (e.g., ziprasidone, iloperidone, clozapine, quetiapine, chlorpromazine), certain antidepressants (e.g., citalopram, fluoxetine), certain antibiotics (e.g., azithromycin, erythromycin, clarithromycin, gatifloxacin, moxifloxacin); and others (e.g., pentamidine, methadone, ondansetron, droperidol).

Since drowsiness may occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking hydroxyzine. Patients should also be advised against the simultaneous use of other CNS depressant drugs, and cautioned that the effects of alcohol may be increased.

Acute Generalized Exanthematous Pustulosis (AGEP)

Hydroxyzine may rarely cause acute generalized exanthematous pustulosis (AGEP), a serious skin reaction characterized by fever and numerous small, superficial, non-follicular, sterile pustules, arising within large areas of edematous erythema. Inform patients about the signs of AGEP, and discontinue hydroxyzine at the first appearance

of a skin rash, worsening of pre-existing skin reactions which hydroxyzine may be used to treat, or any other sign of hypersensitivity. If signs or symptoms suggest AGEP, use of hydroxyzine should not be resumed and alternative therapy should be considered. Avoid cetirizine or levocetirizine in patients who have experienced AGEP or other hypersensitivity reactions with hydroxyzine, due to the risk of cross-sensitivity.

Geriatric Use

A determination has not been made whether controlled clinical studies of hydroxyzine included sufficient numbers of subjects aged 65 and over to define a difference in response from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

The extent of renal excretion of hydroxyzine has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.

Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses of hydroxyzine and observed closely.

Skin and Appendages: Oral hydroxyzine hydrochloride is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in post marketing reports.

Side effects reported with the administration of hydroxyzine hydrochloride are usually mild and transitory in nature.

Anticholinergic: Dry mouth.

Central Nervous System: Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of dose. Involuntary motor activity including rare instances of tremor and convulsions have been reported, usually with doses considerably higher than those recommended. Clinically significant respiratory depression has not been reported at recommended doses.

In post-marketing experience, the following additional undesirable effects have been reported:

Cardiac System: QT prolongation, Torsade de Pointes.

Body as a Whole: Allergic reaction.

Nervous System: Headache.

Psychiatric: Hallucination.

Skin and Appendages: Pruritus, rash, urticaria.

The most common manifestation of hydroxyzine overdose is hypersedation. Other reported signs and symptoms were convulsions, stupor, nausea and vomiting. As in the management of overdose with any drug, it should be borne in mind that multiple agents may have been taken.

If vomiting has not occurred spontaneously, it should be induced. Immediate gastric lavage is also recommended. General supportive care, including frequent monitoring of

the vital signs and close observation of the patient, is indicated. Hypotension, though unlikely, may be controlled with intravenous fluids and levarterenol or metaraminol. Do not use epinephrine as hydroxyzine counteracts its pressor action.

Hydroxyzine overdose may cause QT prolongation and Torsade de Pointes. ECG monitoring is recommended in cases of hydroxyzine overdose.

There is no specific antidote. It is doubtful that hemodialysis would be of any value in the treatment of overdosage with hydroxyzine. However, if other agents such as barbiturates have been ingested concomitantly, hemodialysis may be indicated. There is no practical method to quantitate hydroxyzine in body fluids or tissue after its ingestion or administration.

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: adults, 50 to 100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses.

For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus: adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; children over 6 years, 50 to 100 mg daily in divided doses.

As a sedative when used as a premedication and following general anesthesia: 50 to 100 mg for adults and 0.6 mg/kg of body weight in children.

When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.

As with all potent medication, the dosage should be adjusted according to the patient's response to therapy.

Hydroxyzine Hydrochloride Tablets, USP are available as follows:

10 mg tablets: round, film coated white tablets. Debossed H on one side and 500 on the reverse side.

25 mg tablets: round, film coated white tablets. Debossed H over 501 on one side and plain on the reverse side.

50 mg tablets: round, film coated white tablets. Debossed H over 502 on one side and plain on the reverse side.

Dispense in a tight container as defined in the USP, with a child-resistant closure (as required).

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Mfg For: Heritage Pharmaceuticals Inc.
Eatontown, NJ 07724
NDC 23155-501-01

Mfg Lot:
5/31/2017

D

HYDROXYZINE HCL 25mg 15 Tabs

Generic For: **ATARAX**
Each Tablet Contains: Hydroxyzine HCl, USP 25mg

Lot#
Prod# 217-15

Discard After: 11/18

Packaged and Distributed By: **DIRECT Rx**



Alpharetta, GA 30005

AKLDE

Caution: Federal law prohibits transfer of this drug to any person other than the patient for whom it was prescribed.

RX ONLY-KEEP OUT OF REACH OF CHILDREN

Storage: See package insert. Store between 68-77 degrees F

NDC 61919-217-15

M



May cause DROWSINESS. ALCOHOL may INTENSIFY this effect. Use care when operating dangerous machinery.

- HYDROXYZINE HCL 25mg
NDC 61919-217-15 15 Tabs
Lot Exp Date 11/18
Mfg NDC 23155-501-01
- HYDROXYZINE HCL 25mg
NDC 61919-217-15 15 Tabs
Lot Exp Date 11/18
Mfg NDC 23155-501-01
- HYDROXYZINE HCL 25mg
NDC 61919-217-15 15 Tabs
Lot Exp Date 11/18
Mfg NDC 23155-501-01

Mfg By: Eric Pharma, LLC
Laurelton, NY 11413
NDC 42806-160-01

Mfg Lot: EP180504
RC 4/24/2019 765749



HYDROXYZINE HCL 25mg 30 Tabs

Generic For: **ATARAX**
Each film-coated tablet contains: Hydroxyzine hydrochloride, USP, 25mg

Lot# 24AP1911
Prod# 4206-30

Discard After: 1/31/21
61919-856-30
24AP1911
1/31/21 DAWSONVILLE, AV003 GA 30534

Packaged and Distributed By: **DIRECT Rx**



AV003

Caution: Federal law prohibits transfer of this drug to any person other than the patient for whom it was prescribed.

RX ONLY-KEEP OUT OF REACH OF CHILDREN

Storage: See package insert. Store between 68-77 degrees F

NDC 61919-856-30



- HYDROXYZINE HCL 25mg
NDC 61919-856-30 30 Tabs
Lot 24AP1911 Exp Date 01/21
Mfg NDC 42806-160-01
- HYDROXYZINE HCL 25mg
NDC 61919-856-30 30 Tabs
Lot 24AP1911 Exp Date 01/21
Mfg NDC 42806-160-01
- HYDROXYZINE HCL 25mg
NDC 61919-856-30 30 Tabs
Lot 24AP1911 Exp Date 01/21
Mfg NDC 42806-160-01

Caution: Federal law prohibits transfer of this drug to any person other than the patient for whom it was prescribed. Storage: See package insert. Store between 68-77 degrees F. For RX ONLY. Keep out of reach of children.



HYDROXYZINE HCL

25mg 90 Tabs

Generic For: **ATARAX**
Each Tablet Contains: Hydroxyzine HCL USP., 25mg

Lot# 16JN2002
Prod# 4206-025-90

Discard After: 12/31/21
61919-743-90
16JN2002
12/31/21 Dawsonville, GA 30534
A55D4

Packaged and Distributed By: **DIRECT Rx**



Mfg For: Tera Pharmaceuticals USA, Inc
North Wales, PA 19454

Mfg Lot: 7350010
EW 8/16/2020 1226529
NDC 0093-5061-10

- HYDROXYZINE HCL 25mg
NDC 61919-743-90 90 Tabs
Lot 16JN2002 Exp 12/31/21
Mfg NDC 0093-5061-10
- HYDROXYZINE HCL 25mg
NDC 61919-743-90 90 Tabs
Lot 16JN2002 Exp 12/31/21
Mfg NDC 0093-5061-10
- HYDROXYZINE HCL 25mg
NDC 61919-743-90 90 Tabs
Lot 16JN2002 Exp 12/31/21
Mfg NDC 0093-5061-10

Caution: Federal law prohibits transfer of this drug to any person other than the patient for whom it was prescribed. Dosage: See package insert. Store between 68-77 degrees F. For RX ONLY. Keep out of reach of children.

D

NDC 61919-743-60

HYDROXYZINE HCL

25mg

60 Tabs

Generic For: **ATARAX**
Each Tablet Contains: Hydroxyzine HCL USP., 25mg

Lot# 16JN2002
Prod# 4206-025-60
Packaged and Distributed By: **DIRECT Rx**



Discard After: 12/31/21
61919-743-60
16JN2002 Dawsonville, GA 30534
12/31/21
A55EM

Mfg For: Teva Pharmaceuticals USA, Inc
North Wales, PA 19454
NDC 0093-5061-10
Mfg Lot: 7360010
BW 8/16/2020 RESERVE
HYDROXYZINE HCL 25mg
NDC 61919-743-60 60 Tabs
Lot 16JN2002 Exp 12/31/21
Mfg NDC 0093-5061-10
HYDROXYZINE HCL 25mg
NDC 61919-743-60 60 Tabs
Lot 16JN2002 Exp 12/31/21
Mfg NDC 0093-5061-10
HYDROXYZINE HCL 25mg
NDC 61919-743-60 60 Tabs
Lot 16JN2002 Exp 12/31/21
Mfg NDC 0093-5061-10

Caution: Federal law prohibits transfer of this drug to any person other than the patient for whom it was prescribed. Dosage: See package insert. Store between 68-77 degrees F. For RX ONLY. Keep out of reach of children.

D

NDC 61919-743-30

HYDROXYZINE HCL

25mg

30 Tabs

Generic For: **ATARAX**
Each Tablet Contains: Hydroxyzine HCL USP., 25mg

Lot# 16JN2002
Prod# 4206-025-30
Packaged and Distributed By: **DIRECT Rx**



Discard After: 12/31/21
61919-743-30
16JN2002 Dawsonville, GA 30534
12/31/21
A55EK

Mfg For: Teva Pharmaceuticals USA, Inc
North Wales, PA 19454
NDC 0093-5061-10
Mfg Lot: 7360010
BW 8/16/2020 RESERVE
HYDROXYZINE HCL 25mg
NDC 61919-743-30 30 Tabs
Lot 16JN2002 Exp 12/31/21
Mfg NDC 0093-5061-10
HYDROXYZINE HCL 25mg
NDC 61919-743-30 30 Tabs
Lot 16JN2002 Exp 12/31/21
Mfg NDC 0093-5061-10
HYDROXYZINE HCL 25mg
NDC 61919-743-30 30 Tabs
Lot 16JN2002 Exp 12/31/21
Mfg NDC 0093-5061-10

Caution: Federal law prohibits transfer of this drug to any person other than the patient for whom it was prescribed. Dosage: See package insert. Store between 68-77 degrees F. For RX ONLY. Keep out of reach of children.

NDC 61919-217-30

Hydroxyzine HCL

25mg

30 Tabs


Generic For: **ATARAX**
Each tablet contains: Hydroxyzine hydrochloride, USP 25 mg

Lot# 26SE2208
Prod# 4206-025-30
Packaged and Distributed By: **DIRECT Rx**



Discard After: 6/30/25
61919-217-30
26SE2208 Dawsonville, GA 30534
6/30/25
8PX84

Mfg For: Teva Pharmaceuticals Inc.
Emil Brunsvick, NJ 08816
NDC 23155-501-10
Mfg Lot: 3102205A
9W 8/29/2022 1473652
Hydroxyzine HCL 25mg
NDC 61919-217-30 30 Tabs
Lot 26SE2208 Exp 6/30/25
Mfg NDC 23155-501-10
Hydroxyzine HCL 25mg
NDC 61919-217-30 30 Tabs
Lot 26SE2208 Exp 6/30/25
Mfg NDC 23155-501-10
Hydroxyzine HCL 25mg
NDC 61919-217-30 30 Tabs
Lot 26SE2208 Exp 6/30/25
Mfg NDC 23155-501-10
Hydroxyzine HCL 25mg
NDC 61919-217-30 30 Tabs
Lot 26SE2208 Exp 6/30/25
Mfg NDC 23155-501-10



HYDROXYZINE HCL

hydroxyzine hcl tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:61919-217(NDC:23155-501)
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
-----------------	-------------------	----------

HYDROXYZINE DIHYDROCHLORIDE (UNII: 76755771U3) (HYDROXYZINE - UNII:30S50YM8OG)	HYDROXYZINE DIHYDROCHLORIDE	25 mg
---	-----------------------------	-------

Inactive Ingredients	
Ingredient Name	Strength
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
HYPROMELLOSES (UNII: 3NXW29V3WO)	
MAGNESIUM STEARATE (UNII: 70097M6I3O)	
POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)	
ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)	
CROSPVIDONE (15 MPAS AT 5%) (UNII: 68401960MK)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
POLYSORBATE 80 (UNII: 6OZP39ZG8H)	

Product Characteristics			
Color	white	Score	no score
Shape	ROUND	Size	7mm
Flavor		Imprint Code	H;501
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:61919-217-15	15 in 1 BOTTLE; Type 0: Not a Combination Product	10/30/2017	
2	NDC:61919-217-30	30 in 1 BOTTLE; Type 0: Not a Combination Product	10/30/2017	
3	NDC:61919-217-60	60 in 1 BOTTLE; Type 0: Not a Combination Product	10/30/2017	

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA204279	10/30/2017	

HYDROXYZINE HCL			
hydroxyzine hcl tablet, film coated			
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:61919-856(NDC:42806-160)
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
HYDROXYZINE DIHYDROCHLORIDE (UNII: 76755771U3) (HYDROXYZINE - UNII:30S50YM8OG)	HYDROXYZINE DIHYDROCHLORIDE	25 mg

Inactive Ingredients

Ingredient Name	Strength
POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)	
D&C YELLOW NO. 10 (UNII: 355W5USQ3G)	
CARNAUBA WAX (UNII: R12CBM0EIZ)	
FD&C BLUE NO. 2 (UNII: L06K8R7DQK)	
TALC (UNII: 7SEV7J4R1U)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
HYPROMELLOSES (UNII: 3NXW29V3WO)	
TRIACETIN (UNII: XHX3C3X673)	
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
CROSPROVIDONE (UNII: 2S7830E561)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)	

Product Characteristics

Color	green	Score	no score
Shape	ROUND (biconvex)	Size	8mm
Flavor		Imprint Code	E160
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:61919-856-30	30 in 1 BOTTLE; Type 0: Not a Combination Product	04/30/2019	
2	NDC:61919-856-60	60 in 1 BOTTLE; Type 0: Not a Combination Product	04/30/2019	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA040602	04/30/2019	

HYDROXYZINE HYDROCHLORIDE

hydroxyzine hydrochloride tablet, film coated

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:61919-743(NDC:0093-5061)
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
HYDROXYZINE DIHYDROCHLORIDE (UNII: 76755771U3) (HYDROXYZINE - UNII:30S50YM8OG)	HYDROXYZINE DIHYDROCHLORIDE	25 mg

Inactive Ingredients

Ingredient Name	Strength
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)	
HYPROMELLOSE 2910 (3 MPA.S) (UNII: 0VUT3PMY82)	
HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
CARNAUBA WAX (UNII: R12CBM0EIZ)	
CROSPVIDONE (15 MPA.S AT 5%) (UNII: 68401960MK)	
POLYETHYLENE GLYCOL 8000 (UNII: Q662QK8M3B)	
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)	
POLYDEXTROSE (UNII: VH2XOU12IE)	
HYPROMELLOSE 2910 (50 MPA.S) (UNII: 1IVH67816N)	
TRIACETIN (UNII: XHX3C3X673)	

Product Characteristics

Color	white	Score	no score
Shape	ROUND	Size	6mm
Flavor		Imprint Code	TV;308
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:61919-743-90	90 in 1 BOTTLE; Type 0: Not a Combination Product	06/16/2020	
2	NDC:61919-743-30	30 in 1 BOTTLE; Type 0: Not a Combination Product	06/16/2020	
3	NDC:61919-743-60	60 in 1 BOTTLE; Type 0: Not a Combination Product	06/16/2020	
4	NDC:61919-743-15	15 in 1 BOTTLE; Type 0: Not a Combination Product	06/16/2020	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA088618	06/16/2020	

Labeler - DIRECT RX (079254320)

Registrant - DIRECT RX (079254320)

Establishment

Name	Address	ID/FEI	Business Operations
DIRECT RX		079254320	repack(61919-217, 61919-743) , relabel(61919-856)

Revised: 4/2023

DIRECT RX